Clostridium Difficile Associated Diarrhea in Children with Hematological Malignancy-Experience from a Pediatric Oncologic Centre, Bangladesh

Authors

  • Ferdousi Begum Pediatric Hematology and Oncology Department, National Institute of Cancer Research and Hospital
  • Afiqul Islam Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University
  • Rashidul Haque Infectious Disease Division, International Centre for Diarrheal Disease Research
  • Mohammad Abdal Miah Centre for Medical Education
  • Kazi Khairul Alam Centre for Medical Education
  • Mohammad Anwarul Karim Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University
  • Momena Begum Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University
  • Farida Yasmin Pediatric Hematology and Oncology Department, National Institute of Cancer Research and Hospital

DOI:

https://doi.org/10.6000/1929-4247.2019.08.04.6

Keywords:

C. difficile antigen, C. difficile toxins, Neutropenic diarrhoea, Chemotherapy, C. difficile colonization, Proton- pump inhibitor, Health care infection.

Abstract

Background: Clostridium difficile Associated Diarrhea (CDAD) is considered to be one of the commonest causes of nosocomial diarrhoea worldwide. Gastrointestinal infections in the form of diarrhoea are common in pediatric oncology patients in Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh. The study was conducted to find out the frequency of Clostridium difficile infection (CDI) among diarrheal children with haematological malignancy.

Materials and Methods: This prospective observational study was conducted from April 2012 to March 2013 at the Pediatric Hematology and Oncology Unit, BSMMU, Bangladesh. Total 58 diarrheal episodes occurred in 51 children with various types of haematological malignancies were included consecutively. Faecal samples of the children were sent to International Centre for Diarrheal Disease Research, Bangladesh (ICDDR, B) laboratory for detection of Clostridium difficile antigen (GDH) and toxins (A and/ or B) by Enzyme Immunoassay (EIA).

Results: Among 58 diarrheal episodes 22.4% faecal samples were positive for GDH, but none of the faecal samples was positive for toxin A and or B. There were a significant association with leucopenia, severe neutropenia; usage of meropenem plus vancomycin, cefepime plus amikacin, imipenem, cytarabine and omeprazole with GDH positive diarrheal episodes.

Conclusion: Positive GDH antigen with a negative result for toxin indicates C. difficile colonization. Among GDH positive episodes, a significantly higher proportion of children had leucopenia, severe neutropenia and usage of some drugs known as risk factors for C. difficile infection. To confirm the CDI advanced tests are needed.

References

[1] Coffin SE, Zaoutis TE. Infection control, hospital epidemiology, and patient safety. Infect Dis Clin North Am 2005; 19(3): 647-65.
https://doi.org/10.1016/j.idc.2005.05.002
[2] Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8: 17-26.
https://doi.org/10.1038/nrgastro.2010.190
[3] Dubberke ER, Wertheimer AL. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30(1): 57-66.
https://doi.org/10.1086/592981
[4] Burgner DP, Rfidah H, Beattie TJ, Seal DV. Clostridium difficile after hemolytic uremic syndrome. Arch Dis Child 1993; 69(2): 239-40.
https://doi.org/10.1136/adc.69.2.239
[5] Simon A, Fleisehhack G, Hasan C, Bode U, Engelhart S, Kramer MH. Surveillance for nosocomial and central line-related infections among pediatric haematology-oncologyy patients. Infect Control Hosp Epidemiol 2000; 21(9): 592-6.
https://doi.org/10.1086/501809
[6] Simon A, Ammann RA, Bode U, Fleischhack G, Wenchel HM, Schwamborn D, Gravou C, Schlegel PG, Rutkowski S, Dannenberg C, Korholz D, Laws HJ, Kramer MH. Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis 2008; 8: 70-9.
https://doi.org/10.1186/1471-2334-8-70
[7] Castagnola E, Battaglio T, Bandettini R, Caviglia I, Baldelli I, Nantran M, Moroni C, Garaventa A. Clostridium difficile associated disease in children with solid tumours. Support Care Cancer 2009; 17: 321-4.
https://doi.org/10.1007/s00520-008-0507-0
[8] Anand A, Glatt AE, Clostridium difficile infection associated with antineoplastic chemotherapy; a review. Clin Infect Dis 1993; 17: 109-13.
https://doi.org/10.1093/clinids/17.1.109
[9] Gorschluter M, Glasmacher A, Hahn C, Schakowski F, Ziske C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IGH. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001; 33: 786-91.
https://doi.org/10.1086/322616
[10] Morales Chamorro R, Serrano Blanch R, Mendez Vidal MJ. Pseudomembranous colitis associated with chemotherapy with 5- fluorouracil. Clin Transl Oncol 2005; 7: 258-61.
https://doi.org/10.1007/BF02710173
[11] Tai E, Richardson LC, Townsend J, Howard E, McDonald LC. Clostridium difficile infection among children with cancer. Pediatr Infect Dis J 2011; 30(7): 610-12.
https://doi.org/10.1097/INF.0b013e31820970d1
[12] Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7(7): 526-36.
https://doi.org/10.1038/nrmicro2164
[13] Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18(2): 247-63.
https://doi.org/10.1128/CMR.18.2.247-263.2005
[14] Crobach MJT, Dekkers OM, Wilcox MH, Kujeper EJ. European Society of clinical microbiology and infectious diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15(12): 1053-66.
https://doi.org/10.1111/j.1469-0691.2009.03098.x
[15] Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adult: 2010, update by the society for health care epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31(5): 431-55.
https://doi.org/10.1086/651706
[16] Enoch DA, Butler MJ, Pai S, Aliyu SH, Karas JA. Clostridium difficile in children: Colonisation and disease. J Infect 2011; 63(2): 105-13.
https://doi.org/10.1016/j.jinf.2011.05.016
[17] Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. CID 2008; 46(supple 1): S12-8.
https://doi.org/10.1086/521863
[18] Islam A, Jamal CY, Nahar K, Siddique R, Begum F, Begum M, Yasmin F, Ara Z. Pediatric oncology data-based network (POND) registry initiated in Bangladesh. Pediatric Blood and Cancer 2013; 60(53): 144-5.
[19] Sherief LM, Beshir MR, Kamal NM, Gohar MK, Gohar GK. Diarrhea in neutropenic children with cancer: An Egyptian centre experience, with emphasis on neutropenic enterocolitis. Indian J Med and Ped Oncology 2012; 33(2): 95-101.
https://doi.org/10.4103/0971-5851.99742
[20] Rahman ATM, Mannan MA, Islam A, Jamal CY, Karim MA, Begum H. Outcome of two empirical antibiotic regime in the management of febrile neutropenia in children with cancer. DS (child) HJ 2006; 22(2): 49-53.
[21] Mavros MN, Alexiou VG, Vardakas KZ, Tsokali K, Sardi TA, Falagas ME. Underestimation of Clostridium difficile infection among clinicians: an international survey. Eur J Clin Microbiol Infect Dis 2012; 31(9): 2439-44.
https://doi.org/10.1007/s10096-012-1587-9
[22] Collins DA, Hawkey PM, Riley TV. Epidemiology of Clostridium difficile infection in Asia. Antimicrobial Resistance and Infection Control 2013; 2: 21-30.
https://doi.org/10.1186/2047-2994-2-21
[23] Albert MJ, Faruque ASG, Faruque SM, Sack RB, Mahalanabis D. Case-controll study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. Journal of Clinical Microbiology 1999; 37(11): 3458-64.
[24] Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-7.
https://doi.org/10.1056/NEJM200002103420604
[25] Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994; 18: 181-7.
https://doi.org/10.1093/clinids/18.2.181
[26] Garey KW, Graham G, Gerard L, Dao T, Jiang ZD, Price M, Dupont HL. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother 2006; 40(6): 1030-4.
https://doi.org/10.1345/aph.1H028
[27] Bartlett JG. Antibiotic associated diarrhea. N Eng J Med 2002; 346(5): 334-9.
https://doi.org/10.1056/NEJMcp011603
[28] McFarland LV. Epidemiology of infectious and intragenic nosocomial diarrhea in a cohort of general medicine patients. Am J Infect Control 1995; 23: 295-305.
https://doi.org/10.1016/0196-6553(95)90060-8
[29] Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-asssociated Clostridium difficile infection. J Antimicrob Chemother 2008; 62: 388-396.
https://doi.org/10.1093/jac/dkn163
[30] Delmee M, Van Broeck J, Simon A, Janssens M, Avesani V. Laboratory diagnosis of Clostridium difficile associated diarrhea: a plea for culture. J Med Microbiol 2005; 54: 187-91.
https://doi.org/10.1099/jmm.0.45844-0
[31] Armin S, Shamsian S, Drakhshanfar H. Colonization with Clostridium difficile in children with cancer. Iran J Pediatr 2013; 23(4): 473-6.
[32] Wolf Hagen MJHM, Meijer K, Fluit AC, Jorensma R, Bruinsma RA, Fleer A, Verhoef J. Clinical significance of Clostridium difficile and its toxins in feces of immunocompromised children. Gut 1994; 35: 1608-12.
https://doi.org/10.1136/gut.35.11.1608
[33] Margolin JF, Rabin KR, Steuber CP, Poplack DG. ‘Acute Lymphoblastic Leukemia' in Principles and Practice of Pediatric Oncology, 6th ed. Pizzo PA and Poplack DG, Lippincott, Philadelphia-London 2011; p. 518.
[34] Pai S, Aliyu SH, Enoch DA, Karas JA. Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PloS One 2012; 7(12): e51728.
https://doi.org/10.1371/journal.pone.0051728
[35] Aksoy U, Erbay A, Akisu C, Apa H, Ozkoc S, Ozturk S. Interstinal parasites in children with neoplasms The Turkish Journal of Pediatrics 2003; 45: 129-132.
[36] Morinville V, McDonald J. Clostridium difficile –associated diarrhea in 200 Canadian children. Can J Gastroenterol 2005; 19(8): 497-501.
https://doi.org/10.1155/2005/326296
[37] Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficile –associated disease in children. Infect Control Hosp Epidemiol 2007; 28(11): 1233-5.
https://doi.org/10.1086/520732
[38] Sandora TJ, Fung M, Flaherty K, Helsing L, Scanlon P, Potter-Bynoe G, Gidengil CA, Lee GM. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011; 30: 580-4.
https://doi.org/10.1097/INF.0b013e31820bfb29
[39] McFarland LV, Brandmarker SA, Guandalini S. Pediatric Clostridium difficile: A Phantom Menace or clinical reality? J Ped Gastroenterol and Nutr 2000; 31(3): 220-31.
https://doi.org/10.1097/00005176-200009000-00004
[40] Murabata M, Kato H, Yano H. Intestinal colonization and nosocomial spread of Clostridium difficile in pediatric cancer patients under long-term hospitalization 2008; 82(5): 419-26.
https://doi.org/10.11150/kansenshogakuzasshi1970.82.419
[41] Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-7.
https://doi.org/10.1086/430315
[42] Turco R, Martinelli M, Miele E, Roscetto E, Pezzo MD, Greco L, Staiano A. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010; 31: 754-9.
https://doi.org/10.1111/j.1365-2036.2009.04229.x

Downloads

Published

2019-11-12

Issue

Section

General Articles